etoposide has been researched along with ly335979 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baughman, TM; Bumol, TF; Cao, J; Dantzig, AH; Ehlhardt, WJ; Law, KL; Shepard, RL; Starling, JJ | 1 |
| Al-Ali, AAA; Dillen, L; Holm, R; Nielsen, CU; Pijpers, I; Sandra, L; Snoeys, J; Vermeulen, A; Versweyveld, D | 1 |
2 other study(ies) available for etoposide and ly335979
| Article | Year |
|---|---|
Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Binding Sites; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Membrane; Cell Survival; Dibenzocycloheptenes; Drug Resistance, Multiple; Etoposide; Humans; Kinetics; Leukemia P388; Lung Neoplasms; Mice; Mice, Nude; Paclitaxel; Protein Binding; Quinolines; Transplantation, Heterologous; Tumor Cells, Cultured; Vinblastine | 1996 |
High-dose etoposide formulations do not saturate intestinal P-glycoprotein: Development, stability, and pharmacokinetics in Sprague-Dawley rats.
Topics: Administration, Oral; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Caco-2 Cells; Dibenzocycloheptenes; Drug Compounding; Drug Stability; Ethanol; Etoposide; Humans; Injections, Intravenous; Intestinal Absorption; Intestinal Mucosa; Male; Models, Biological; Poloxamer; Polyvinyls; Povidone; Quinolines; Rats, Sprague-Dawley; Solubility | 2020 |